ArticleAudiology & neuro-otology2026
Audiological Outcomes of Salvage Intratympanic Corticosteroid Therapy in Idiopathic Sudden Sensorineural Hearing Loss.
Article in Audiology & neuro-otology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Intratympanic corticosteroids (ITCs) are used to treat patients with idiopathic sudden sensorineural hearing loss (ISSNHL) when systemic therapy has been unsuccessful. However, the efficacy of this treatment remains uncertain.
methodsWe retrospectively analysed ISSNHL patients at a tertiary reference centre, who received ITC injections following unsuccessful systemic corticosteroid therapy administered either orally or intravenously. Patients were eligible for ITC if they showed insufficient improvement after systemic treatment, defined as a remaining hearing loss of ≥30 dB HL in at least three frequencies. They received three intratympanic injections of 0.3-0.5 mL dexamethasone (4 mg/mL) within 10-14 days from first to last injection. Changes in pure-tone audiometry were assessed.
resultsA total of 34 patients met the inclusion criteria for the study. The mean pure tone average (PTA) improvement was 10.62 dB HL. A total of 18 (53%) patients showed hearing improvement of ≥10 dB HL (of these: n = 11 (32%) ≥20 dB HL, n = 2 (6%) ≥30 dB HL). Sixteen (47%) patients had an improvement of less than 10 dB HL. In addition to the PTA analysis, individual frequencies at 0.5 kHz, 1 kHz, 2 kHz, and 4 kHz were examined and showed significant improvements, with p values ranging from 0.007 to 0.037. Regarding the World Health Organization grading of hearing impairment, 13 (38.2%) patients improved by at least one category. Concomitant vestibular syndrome (n = 5) showed a marginally non-significant trend (p = 0.066) towards less improvement. There was no significant correlation between age and degree of hearing loss (p = 0.123). Complications of ITC were minimal, with only 1 patient reporting a temporary headache following injection.
conclusionIn patients with persistent ISSNHL after systemic corticosteroid therapy, ITC injections resulted in limited hearing improvement. Despite the low risks associated with this therapy, its routine use should be considered on a case-by-case evaluation. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.